The evidence on peptides — delivered weekly. Subscribe free →

Angiotensin (1-7)

low risk

Also: Ang(1-7) · MasR agonist · ACE2 product

Moderate Evidence Research Only

Angiotensin (1-7) is the primary product of ACE2 enzymatic activity — the counter-regulatory arm of the renin-angiotensin system. Gained significant research attention post-COVID-19 (ACE2 is the SARS-CoV-2 receptor). Demonstrates cardiovascular protection, anti-fibrosis, and metabolic benefits in human trials.

Molecular Weight
899.1 Da
Formula
C34H49N9O9
Common Dosing
Varies by indication; IV infusion and SC formulations in trials
Category
therapeutic
Last Reviewed
2025-01-15

Reported Benefits

Cardiovascular protection

Moderate Evidence 34 studies

Human trials show blood pressure reduction, endothelial improvement, and anti-fibrotic effects.

Mechanism of Action

Activates Mas receptor (MasR); opposes Angiotensin II/AT1R axis; produces vasodilation, natriuresis, anti-inflammatory, and anti-fibrotic effects.

ACE2 Pathway Context

Angiotensin (1-7) is the ‘good’ product of the renin-angiotensin system — opposing the pro-hypertensive, pro-fibrotic Angiotensin II. The COVID-19 pandemic dramatically increased research into ACE2/Ang(1-7) physiology.

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Hypotension (dose-dependent)
  • •Flushing

Contraindications

  • •Severe hypotension
  • •Pregnancy

Primary Uses

Cardiovascular protectionAnti-hypertensionAnti-fibroticMetabolic health

Related Peptides

alamandinebpc-157

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe Angiotensin (1-7)?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.